47P Phase I study to assess the safety and efficacy of P-BCMA-ALLO1: A fully allogeneic CAR-T therapy, in patients with relapsed/refractory multiple myeloma (RRMM)
Kocoglu, M.H., Asch, A., Ramakrishnan, A., Bachier, C., Martin, T., Rodriguez, T., McArthur, K., Martin, C., Namini, H., Ostertag, E., Spear, M., Christie, E., Belani, R., Zhang, M., Cranert, S., Coronella, J., Shedlock, D., Costello, C.
Published in Immuno-oncology technology (01.12.2022)
Published in Immuno-oncology technology (01.12.2022)
Get full text
Journal Article